Literature Review: Kidney Transplant Patients, Mutant Patients, and Low-Dose Tacrolimus Therapy:

KARTAVYA CHETANKUMAR PATEL
SAL INSTITUTE OF PHARMACY

Introduction

- Kidney transplantation is an established treatment for end-stage renal disease, but it requires lifelong immunosuppressive therapy to prevent rejection of the transplanted organ. Tacrolimus, a calcineurin inhibitor, is a cornerstone of this therapy. However, the dosing of tacrolimus can be challenging, particularly in patients with genetic variations that affect drug metabolism and in those requiring lower doses due to side effects or other health concerns. This literature review synthesizes current research findings on the interplay between tacrolimus therapy, genetic factors, and innovative treatment strategies, particularly for kidney transplant patients with mutations that may impact drug efficacy and safety.

- **Genetic Factors and Tacrolimus Metabolism:**

The metabolism of tacrolimus is significantly influenced by genetic polymorphisms, particularly those related to the CYP4503A5 genotype. Jacobson et al. (2011) demonstrated that African American patients, who often carry the CYP4503A51 allele, may require higher doses of tacrolimus to achieve therapeutic levels, which could be particularly relevant for mutant patients with unique metabolic profiles. This highlights the necessity for personalized medical approaches in tacrolimus therapy to optimize dosing and minimize toxicity.

Further studies by Glowacki et al. (2011) and Elens et al. (2013) corroborate the importance of genetic testing in tailoring tacrolimus therapy. They found that specific genetic variations can lead to significant differences in drug metabolism, indicating that mutant patients may require individualized dosing strategies to avoid subtherapeutic levels or toxicity. The implications of these findings suggest a pressing need for routine genetic screening in kidney transplant recipients to guide tacrolimus dosing effectively.

Innovative Strategies for Tacrolimus Management

Recent research has explored innovative strategies to reduce the required doses of tacrolimus while maintaining graft function and minimizing side effects. For instance, Peng et al. (2013) conducted a pilot study combining mesenchymal stem cells (MSCs) with a reduced dose of tacrolimus, which resulted in fewer acute rejections and stable renal function. This strategy could be particularly advantageous for mutant patients who are more susceptible to the adverse effects of higher tacrolimus doses, supporting the potential for individualized immunosuppressive therapy.

Additionally, Gaber et al. (2013) investigated a new formulation of tacrolimus designed for once-daily dosing. This approach not only improves medication adherence but may also enable lower dosing while maintaining effective drug levels, which is especially beneficial for patients prone to side effects from higher doses. Langone et al. (2015) further highlighted the potential of this new formulation to alleviate common side effects, such as tremor, which is crucial for enhancing the quality of life for kidney transplant patients.

Variability in Tacrolimus Exposure

Intrapatient variability (IPV) in tacrolimus exposure can significantly impact long-term outcomes. Shuker et al. (2016) found that high IPV is associated with poor outcomes, emphasizing the importance of consistent tacrolimus levels, particularly in mutant patients who may experience unpredictable drug metabolism. Leino et al. (2018) also reported variability in tacrolimus levels even among adherent patients, reinforcing the need for vigilant monitoring and management of tacrolimus therapy to mitigate risks associated with high IPV.

Moreover, Guo et al. (2018) provided insights into the role of gut microbiota in tacrolimus metabolism, suggesting that interactions between drugs and gut bacteria could influence drug exposure and efficacy. Understanding these interactions could lead to more personalized approaches in managing tacrolimus therapy, particularly for mutant patients with unique metabolic profiles.

Special Considerations

For kidney transplant patients considering pregnancy, tacrolimus management becomes particularly critical. Shah and Verma (2016) underscored the need for careful monitoring and adjustments in tacrolimus dosing to ensure both maternal and fetal safety. This is especially pertinent for mutant patients who may have additional risks associated with their genetic predispositions and the challenges of pregnancy.

In light of the COVID-19 pandemic, Busque et al. (2011) highlighted the necessity for careful monitoring and potential adjustments to immunosuppressive therapy to prevent graft failure. The unique vulnerabilities of mutant patients during infectious disease outbreaks necessitate individualized care strategies.

Knowledge Gaps and Future Directions

Despite the advancements in understanding tacrolimus therapy, several knowledge gaps remain. For instance, while genetic testing is recognized as essential for optimizing tacrolimus dosing, the extent to which various genetic polymorphisms interact with other factors (such as environmental influences and gut microbiota) remains poorly understood. Future research should explore these complex interactions to refine personalized treatment strategies further.

- Moreover, while innovative therapies like MSCs and new formulations of tacrolimus show promise, there is a need for larger, long-term studies to validate their efficacy and safety in diverse patient populations, particularly mutant patients. Investigating alternative immunosuppressants that may offer similar efficacy with fewer side effects could also provide valuable insights for managing patients who are intolerant to standard tacrolimus therapy.

Conclusions

The management of tacrolimus therapy in kidney transplant patients, particularly those with mutations affecting drug metabolism, is a complex but critical area of research. Genetic factors, innovative therapeutic strategies, and the need for individualized care are paramount in optimizing patient outcomes while minimizing risks. As research continues to evolve, it is essential to address existing knowledge gaps and explore new avenues for improving the management of tacrolimus in this vulnerable population.

References:

1. Glowacki, F.., Lionet, A.., Buob, D.., Labalette, M.., Allorge, D.., Provôt, F.., Hazzan, M.., Noël, C.., Broly, F.., & Cauffiez, C.. (2011). CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association , 26 9 , 3046-50 . http://doi.org/10.1093/ndt/gfr253

2. Shuker, N.., Shuker, L.., Rosmalen, J.., Roodnat, J.., Borra, L. C.., Weimar, W.., Hesselink, D.., & Gelder, T.. (2016). A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. Transplant International , 29 . http://doi.org/10.1111/tri.12798

3. Gatault, P.., Kamar, N.., Kamar, N.., Büchler, M.., Colosio, C.., Bertrand, D.., Durrbach, A.., Albano, L.., Rivalan, J.., Meur, Y.., Essig, M.., Bouvier, N.., Legendre, C.., Moulin, B.., Heng, A.., Weestel, Pierre-François., Sayegh, J.., Charpentier, B.., Rostaing, L.., Rostaing, L.., Thervet, E.., & Lebranchu, Y.. (2017). Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. American Journal of Transplantation , 17 , 1370 - 1379 . http://doi.org/10.1111/ajt.14109

4. Brooks, E.., Tett, S.., Isbel, N.., & Staatz, C.. (2016). Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?. Clinical Pharmacokinetics , 55 , 1295-1335 . http://doi.org/10.1007/s40262-016-0396-1

5. Elens, L.., Capron, A.., Schaik, R. V. van., Meyer, M. De., Pauw, L. De., Eddour, D. C.., Latinne, D.., Wallemacq, P.., Mourad, M.., & Haufroid, V.. (2013). Impact of CYP3A422 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation: Toward Updated Genotype-Based Dosage Guidelines. Therapeutic Drug Monitoring , 35 , 608–616 . http://doi.org/10.1097/FTD.0b013e318296045b

6. Busque, S.., Cantarovich, M.., Mulgaonkar, S.., Gaston, Robert S.., Gaber, A. O.., Mayo, Patrick R.., Ling, S.., Huizinga, R.., & Meier-Kriesche, H.. (2011). The PROMISE Study: A Phase 2b Multicenter Study of Voclosporin (ISA247) Versus Tacrolimus in De Novo Kidney Transplantation. American Journal of Transplantation , 11 . http://doi.org/10.1111/j.1600-6143.2011.03763.x

7. Langone, A.., Steinberg, S.., Gedaly, R.., Chan, L.., Shah, T.., Sethi, K.., Nigro, V.., Morgan, J.., Formica, R.., Barr, Yousri M.., Brennan, D.., El-Amm, J.., Kozłowski, T.., Matas, A.., West-Thielke, P.., & Kistler, K.. (2015). Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clinical Transplantation , 29 , 796 - 805 . http://doi.org/10.1111/ctr.12581

8. Peng, Yanwen., Ke, M.., Xu, Lu., Liu, Longshan., Chen, Xiaoyong., Xia, W.., Li, Xiaobo., Chen, Zheng., Ma, Jun-jie., Liao, D.., Li, Guang-hui., Fang, Jia-li., Pan, G.., & Xiang, A.. (2013). Donor-Derived Mesenchymal Stem Cells Combined With Low-Dose Tacrolimus Prevent Acute Rejection After Renal Transplantation: A Clinical Pilot Study. Transplantation Journal , 95 , 161–168 . http://doi.org/10.1097/TP.0b013e3182754c53

9. Jacobson, P.., Oetting, W.., Brearley, Ann M.., Leduc, R.., Guan, W.., Schladt, D.., Matas, A.., Lamba, V.., Julian, B.., Mannon, R.., & Israni, A.. (2011). Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium. Transplantation , 91 , 300-308 . http://doi.org/10.1097/TP.0b013e318200e991

10. Shah, Silvi., & Verma, Prasoon. (2016). Overview of Pregnancy in Renal Transplant Patients. International Journal of Nephrology , 2016 . http://doi.org/10.1155/2016/4539342

11. Guo, Yukuang., Crnkovic, Camila M.., Won, Kyoung-Jae., Yang, Xiaotong., Lee, J.., Orjala, J.., Lee, Hyunwoo., & Jeong, Hyunyoung. (2018). Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites. Drug Metabolism and Disposition , 47 , 194 - 202 . http://doi.org/10.1124/dmd.118.084772

12. Gaber, A.., Alloway, R.., Bodziak, K.., Kaplan, B.., & Bunnapradist, S.. (2013). Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients. Transplantation , 96 , 191 - 197 . http://doi.org/10.1097/TP.0b013e3182962cc1

13. Leino, A.., King, Eileen C.., Jiang, Wenlei., Vinks, A.., Klawitter, J.., Christians, U.., Woodle, E.., Alloway, R.., & Rohan, Jennifer M.. (2018). Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. American Journal of Transplantation , 19 , 1410 - 1420 . http://doi.org/10.1111/ajt.15199